When was DemeRx founded?

DemeRx was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Where is DemeRx located?

DemeRx is headquartered in Miami, United States.

Who is the current CEO of DemeRx?

Deborah C Mash of DemeRx. They have also founded 1 company.

How many employees does DemeRx have?

As of Sep 30, 2026, the latest employee count at DemeRx is 9.

Is DemeRx a funded company?

DemeRx is a funded company, having raised a total of $5.43M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 01, 2013.

When was the latest funding round of DemeRx?

DemeRx's latest funding was a $***** Series A round on May 08, 2015, with participation from 0 investor.

Where does DemeRx rank among its competitors?

DemeRx ranks 10th amongst 56 active competitors, of which 15 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Adial Pharmaceuticals, which secured $64M in Jun, 2026.

Who are the top competitors of DemeRx?

DemeRx's top competitors include Indivior, Adial Pharmaceuticals and Aelis Farma. Among them, Adial Pharmaceuticals secured the most recent funding round in June, 2026.

DemeRx - 2026 Company Profile, Team, Funding & Competitors

DemeRx is a series A company based in Miami (United States), founded in 2010 by Deborah C Mash. It operates as a Developer of non-addicting alternatives for opioid de-addiction. DemeRx has raised $5.43M in funding. The company has 56 active competitors, including 15 funded and 14 that have exited. Its top competitors include companies like Indivior, Adial Pharmaceuticals and Aelis Farma.

Company Details

DemeRx is a developer of drugs for detoxification from opioids. The lead products developed are non-addicting alternatives to OST called Ibogaine (indole alkaloid) and Noribogaine (Ibogine's active metabolite). The drug Noribogine is used for office-based opioid-dependent withdrawal treatment and detoxification of incarcerated addicts.

Website: www.demerx.com/
Email ID: *****@demerx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2010

Location

Miami, United States

Stage

Series A

Total Funding

$5.43M in 2 rounds

Latest Funding Round

Series A, May 08, 2015, $*****

Ranked

10^th among 56 active competitors

Employee Count

9 as on Sep 30, 2026

Similar Companies

Indivior & 61 more

View DemeRx's full profile

DemeRx has raised a total funding of $5.43M over 2 rounds. Its first funding round was on Mar 01, 2013.

Here is the list of recent funding rounds of DemeRx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 08, 2015	5551004	Series A	1026587	7246003	1209026	7384108
Mar 01, 2013	9843304	Series A	7347692	6568495	3699247	2878462

Access funding benchmarks and valuations. Sign up today!

View details of DemeRx's funding rounds and investors

The founders of DemeRx is Deborah C Mash. Deborah C Mash is the CEO of DemeRx.

Here are the details of DemeRx's key team members:

Deborah C Mash: Founder & CEO of DemeRx.
Contact Info: 1 email address

View details of DemeRx's Founder profiles and Board Members

DemeRx's employee count trend

DemeRx has 9 employees as of Sep 26. Here is DemeRx's employee count trend over the years:

Uncover DemeRx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DemeRx include Indivior, Adial Pharmaceuticals and Aelis Farma. Here is the list of Top 10 competitors of DemeRx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Indivior 2014, Richmond Hill (United States), Public	Therapeutics for addiction treatment	-	Digital Pharma Lab, Athyrium Capital Management ... & 1 others	65/100
2nd	Adial Pharmaceuticals 2010, Charlottesville (United States), Public	Developer of therapeutics for the treatment of addictions	$7.7M	Coastlands Capital, Boxer Capital & 3 others	57/100
3rd	Aelis Farma 2013, Bordeaux (France), Public	Developer of small molecule drugs targeting CB1 receptor for CNS diseases	$14M	Bpifrance, Inserm Transfert & 10 others	56/100
4th	Braeburn 2012, Philadelphia (United States), Series D	Developing long acting formulation for opioid addiction	$110M	RA Capital Management, New Leaf Venture Partners ... & 5 others	56/100
5th	Ethypharm 1977, Saint Cloud (France), Acquired	Developer of therapies for the treatment of pain and addiction	$248M	Astorg Partners, Biovail & 7 others	55/100
6th	Achieve Life Sciences 1991, Seattle (United States), Public	Developer of plant-based alkaloid for treating smoking cessation	-	Marshall Wace, Frazier Life Sciences & 7 others	54/100
7th	Myosin Therapeutics 2020, Jupiter (United States), Seed	Developer of therapeutics for CNS-based disorders	$6M	Florida Opportunity Fund, DeepWork Capital ... & 7 others	53/100
8th	Biotie 1998, Turku (Finland), Acquired	Commercial Stage biotech company developing drugs against CNS disease.	$150M	Foresite Capital, Versant Ventures & 10 others	50/100
9th	Titan Pharma 1992, San Francisco (United States), Public	A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases	-	Blue Harbour Asset Management, Gates & 5 others	50/100
10th	DemeRx 2010, Miami (United States), Series A	Developer of non-addicting alternatives for opioid de-addiction	$5.43M	-	49/100